Sugi Predict

Sugi Predict / Compounds / SCHEMBL16048631

SCHEMBL16048631

SCHEMBL16048631

COC(=O)c1ccc(NS(C)(=O)=O)nc1

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MAPK1 P28482 2/20 0.56
▸ KDM4E B2RXH2 2/20 0.53
▸ L3MBTL1 Q9Y468 1/20 0.53
▸ SMN1; SMN2 Q16637 1/20 0.51
▸ HSD17B10 Q99714 1/20 0.51
▸ POLB P06746 1/20 0.49
▸ STS P08842 1/20 0.45
▸ CA1 P00915 1/20 0.44
▸ CA2 P00918 1/20 0.44
▸ HPGD P15428 2/20 0.44
▸ HTT P42858 1/20 0.44
▸ HCAR3 P49019 2/20 0.44
▸ ALDH1A1 P00352 1/20 0.44
▸ HDAC3 O15379 1/20 0.43
▸ HDAC4 P56524 1/20 0.43
▸ HDAC1 Q13547 1/20 0.43
▸ HDAC7 Q8WUI4 1/20 0.43
▸ HDAC2 Q92769 1/20 0.43
▸ HDAC10 Q969S8 1/20 0.43
▸ HDAC11 Q96DB2 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16076748 0.85 HPGD (0.62) MAPK1KDM4ESMN1; SMN2HSD17B10STS
SCHEMBL731875 0.83 HCAR3 (0.64) HCAR3
SCHEMBL1877716 0.82 NNMT (0.65) KDM4EL3MBTL1SMN1; SMN2HCAR3NNMT
SCHEMBL13064470 0.81 HDAC3 (0.62) MAPK1KDM4EL3MBTL1SMN1; SMN2POLB
SCHEMBL246879 0.80 ALDH1A1 (0.60) KDM4EPOLBHPGDALDH1A1HDAC3
SCHEMBL6984008 0.80 HCAR3 (0.68) MAPK1KDM4EL3MBTL1CA1CA2
SCHEMBL6074331 0.78 HDAC3 (0.47) HCAR3HDAC3HDAC4HDAC1HDAC7
SCHEMBL13739418 0.78 MAPK1 (0.61) MAPK1KDM4EL3MBTL1STSCA1
SCHEMBL14799023 0.78 POLB (0.49) MAPK1KDM4EL3MBTL1SMN1; SMN2HSD17B10
SCHEMBL1854705 0.77 MAPK1 (0.59) MAPK1KDM4EL3MBTL1SMN1; SMN2HCAR3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11851428-B2 Activator of TREK (TWIK RElated K+channels) channels ONO PHARMACEUTICAL CO., LTD. (JP) 2023-12-26 — — US disclosed
US-20230110165-A1 Substituted Imidazo[4,5-c]pyridine Compounds and Compositions Thereof PROXIMAGEN LLC (US) 2023-04-13 — — US disclosed
US-11512082-B2 Substituted imidazo[4,5-c]pyridine compounds and compositions thereof PROXIMAGEN, LLC (US) 2022-11-29 — — US disclosed
US-20210347773-A1 ACTIVATOR OF TREK (TWIK RELATED K+ CHANNELS) CHANNELS ONO PHARMACEUTICAL CO., LTD. (JP) 2021-11-11 — — US disclosed
US-20210347773-A1 ACTIVATOR OF TREK (TWIK RELATED K+ CHANNELS) CHANNELS ONO PHARMACEUTICAL CO., LTD. (JP) 2021-11-11 — — US disclosed
US-11046683-B2 Activator of TREK (TWIK RElated K+ channels) channels ONO PHARMACEUTICAL CO., LTD. (JP) 2021-06-29 — — US disclosed
US-11046683-B2 Activator of TREK (TWIK RElated K+ channels) channels ONO PHARMACEUTICAL CO., LTD. (JP) 2021-06-29 — — US disclosed
US-20200262835-A1 COMPOUNDS PROXIMAGEN, LLC (US) 2020-08-20 — — US disclosed
US-10590125-B2 Compounds PROXIMAGEN, LLC (US) 2020-03-17 — — US disclosed
EP-3558992-A1 ACTIVATOR OF TREK (TWIK RELATED K+ CHANNELS) CHANNELS ONO Pharmaceutical Co., Ltd. (JP) 2019-10-30 — — EP disclosed
US-20190322662-A1 ACTIVATOR OF TREK (TWIK RELATED K+ CHANNELS) CHANNELS ONO PHARMACEUTICAL CO., LTD. (JP) 2019-10-24 — — US disclosed
US-20190322662-A1 ACTIVATOR OF TREK (TWIK RELATED K+ CHANNELS) CHANNELS ONO PHARMACEUTICAL CO., LTD. (JP) 2019-10-24 — — US disclosed
WO-2018110669-A1 ACTIVATOR OF TREK (TWIK RELATED K+ CHANNELS) CHANNELS ONO PHARMACEUTICAL CO., LTD. (JP) 2018-06-21 — — WO disclosed
US-20160326172-A1 NEW COMPOUNDS PROXIMAGEN, LLC 2016-11-10 — — US disclosed
US-9428498-B2 Substituted imidazo[4,5-c]pyridine compounds and compositions thereof PROXIMAGEN LIMITED (GB) 2016-08-30 — — US disclosed
US-20140275040-A1 NEW COMPOUNDS PROXIMAGEN LIMITED (GB) 2014-09-18 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10590125-B2 Compounds ALOX15B, ALOX12, ALOX15 MAPK1 2978/4885KDM4E 2903/4885L3MBTL1 4580/4885
US-11512082-B2 Substituted imidazo[4,5-c]pyridine compounds and compositions thereof PNPO, XDH, EPX MAPK1 2375/4885KDM4E 1141/4885L3MBTL1 4677/4885
US-20160326172-A1 NEW COMPOUNDS SSB, ALOX15B, ALOX12 MAPK1 2898/4885KDM4E 3511/4885L3MBTL1 4701/4885
US-20140275040-A1 NEW COMPOUNDS SSB, ALOX15B, ALOX12 MAPK1 2898/4885KDM4E 3511/4885L3MBTL1 4701/4885
US-11851428-B2 Activator of TREK (TWIK RElated K+channels) channels KCNJ11, KCNJ1, KCNJ8 MAPK1 1817/4885KDM4E 3251/4885L3MBTL1 3207/4885
US-20190322662-A1 ACTIVATOR OF TREK (TWIK RELATED K+ CHANNELS) CHANNELS KCNJ11, KCNJ1, KCNJ8 MAPK1 1817/4885KDM4E 3251/4885L3MBTL1 3207/4885
US-11046683-B2 Activator of TREK (TWIK RElated K+ channels) channels KCNJ11, KCNJ1, KCNJ8 MAPK1 1817/4885KDM4E 3251/4885L3MBTL1 3207/4885
US-20230110165-A1 Substituted Imidazo[4,5-c]pyridine Compounds and Compositions Thereof PNPO, XDH, EPX MAPK1 2375/4885KDM4E 1141/4885L3MBTL1 4677/4885
US-20200262835-A1 COMPOUNDS QSOX1, AOX1, EPX MAPK1 1946/4885KDM4E 3055/4885L3MBTL1 4236/4885
US-20210347773-A1 ACTIVATOR OF TREK (TWIK RELATED K+ CHANNELS) CHANNELS KCNJ11, KCNJ1, KCNJ8 MAPK1 1817/4885KDM4E 3251/4885L3MBTL1 3207/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.